Vernalis plc
| Public company | |
| Traded as | LSE: VER NASDAQ: VNLS |
| Industry | Biotechnology |
| Founded | 2003 |
| Headquarters | Winnersh, United Kingdom |
Key people |
Ian Garland (CEO) Peter Fellner (Executive chairman) |
| Products | Frovatriptan, Apokyn |
Number of employees | 200 |
| Website | vernalis.com |
Vernalis plc is a British based biotech company founded in 2003 by the merger of Vernalis Group with British Biotech in a deal valued at £90 million.[1] The merger allowed British Biotech to ditch its historic but tarnished name.[2]
The company has marketed two drug products; Frovatriptan,[3] to treat migraine, and Apokyn, an apomorphine-based drug for advanced Parkinson's disease.[4]
The company has a development pipeline focused on CNS disease and oncology, and collaborates with pharmaceutical companies including Novartis, Servier, ChemGenex and Serono. It is listed on the London Stock Exchange and is a constituent of the FTSE Fledgling Index.
References
- ↑ "Vernalis agrees £91m merger plan with British Biotech". Advances in Life Science. ALS. 2003. Retrieved 3 July 2003.
- ↑ "Fifth Report". Select Committee on Science and Technology. House of Commons. 1998. Retrieved 28 November 2007.
- ↑ "Patient Information Sheet – Frovatriptan succinate (marketed as Frova)". Food and Drug Administration. July 2006. Archived from the original on 29 September 2007. Retrieved 28 November 2007.
- ↑ "Apokyn". FDA. 2004. Retrieved 29 July 2004.
